within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AK02_Teriflunomide;
model Teriflunomide 
   extends Pharmacolibrary.Drugs.ATC.L.L04AK02;

  annotation(Documentation(
    info ="<html><body><p>Teriflunomide is an oral immunomodulatory drug approved for the treatment of relapsing forms of multiple sclerosis (MS). It works by inhibiting the enzyme dihydroorotate dehydrogenase, thus interfering with de novo pyrimidine synthesis in rapidly dividing cells such as activated lymphocytes.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult patients with multiple sclerosis, both sexes, typical dose, without significant comorbidities.</p><h4>References</h4><ol><li><p>Sartori, A, et al., &amp; Freedman, MS (2014). Teriflunomide: a novel oral treatment for relapsing multiple sclerosis. <i>Expert opinion on pharmacotherapy</i> 15(7) 1019–1027. DOI:<a href=&quot;https://doi.org/10.1517/14656566.2014.902936&quot;>10.1517/14656566.2014.902936</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24742277/&quot;>https://pubmed.ncbi.nlm.nih.gov/24742277</a></p></li><li><p>Nwankwo, E, et al., &amp; Rivey, MP (2012). Emerging oral immunomodulating agents - focus on teriflunomide for the treatment of multiple sclerosis. <i>Degenerative neurological and neuromuscular disease</i> 2 15–28. DOI:<a href=&quot;https://doi.org/10.2147/DNND.S29022&quot;>10.2147/DNND.S29022</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30890875/&quot;>https://pubmed.ncbi.nlm.nih.gov/30890875</a></p></li><li><p>Rouini, MR, et al., &amp; Ghasemian, E (2020). Pharmacokinetics and Bioequivalence Studies of Teriflunomide in Healthy Iranian Volunteers. <i>Clinical pharmacology in drug development</i> 9(3) 341–345. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.725&quot;>10.1002/cpdd.725</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31379101/&quot;>https://pubmed.ncbi.nlm.nih.gov/31379101</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Teriflunomide;
